In the NACC dataset, APOE4 carriers have an elevated risk of clinician reported myocardial infarction among people with a concurrent AD diagnosis (n = 4,569) but not in those without an AD diagnosis (n = 13,009) at the baseline assessment of clinician reported comorbidities in the past 12 months. Here, APOE is linked to myocardial infarction.